Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone

• Status: Completed
• Trial end date: 2013-02-01
• Target enrollment: 0
• Participant gender: All

Summary

A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Clinical trial to Investigate Blonanserin in Treatment of Schizophrenia when compared with Risperidone

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sumitomo Pharmaceutical (Suzhou) Co., Ltd.
• Treatments: Risperidone

Criteria

Inclusion Criteria:

• Subject met Diagnostic and Statistical Manual of Mental Disorders(DSM)-IV-Text Revision(TR) criteria for a primary diagnosis of schizophrenia

• Patients are 18≤age<65 years of age on the day when informed consent is obtained.

• Subject had a PANSS total score ≥70 and 120≥ at Screening

• Subject had a score ≥4 on the PANSS at Screening and Baseline.

• Subjects are willing and able to comply with study protocol including treatment in hospital.

• Subjects or their legal guardians have signed the written informed consent form.

Exclusion Criteria:

• The subject was treatment with other Investigate product within 30 days.

• Subject had a history of treatment with long-acting drug for anti schizophrenia within 56 days.

• Subject had a history of treatment with clozapine within 28 days.

• Subject With parkinson disease,etc